Therapeutic | Benralizumab |
Target | IL5RA |
Heavy Chain | EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVIHWVRQRPGQGLAWMGYINPYNDGTKYNERFKGKVTITSDRSTSTVYMELSSLRSEDTAVYLCGREGIRYYGLLGDYWGQGTLVTVSS |
Light Chain | DIQMTQSPSSLSASVGDRVTITCGTSEDIINYLNWYQQKPGKAPKLLIYHTSRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGYTLPYTFGQGTKVEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (August '23) | Approved |
Estimated Status (August '23) | Active |
Recorded Developmental Technology | POTELLIGENT Technology |
INN Year Proposed | 2009 |
INN Year Recommended | 2010 |
Companies Involved | AstraZeneca, Cincinnati Children's Hospital Medical Center, Kyowa Hakko, Kyowa Hakko Kirin, McMaster University, MedImmune, National Jewish Medical and Research Center, BioWa |
Conditions Approved | Asthma |
Conditions Active | Chronic obstructive pulmonary disease, Nasal polyps, Atopic dermatitis, Churg-Strauss syndrome, Hypereosinophilic syndrome, Rhinosinusitis, Eosinophilic gastroenteritis |
Conditions Discontinued | Skin disorders |
Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]